Invitrogen opens Australian cGMP manufacturing facility

Thursday, 25 August, 2005

Invitrogen has opened a AU$3.4 million cGMP bioproduction facility focused on the development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.

cGMP refers to good manufacturing practices required in the design and operation of the facility, processes and quality systems in order to serve global pharmaceutical companies. Invitrogen's site also features new process technology and automation optimised for the standards expected by biopharmaceutical customers.

Australia and New Zealand are among the few countries regarded as being BSE free, as well as having a lower incidence of other viral diseases prevalent in other countries. As a result, global pharmaceutical companies are seeking secure supply of locally produced biotechnology products.

This reputation is important as it encourages global biopharmaceutical customers to source product from this part of the world. It is a global advantage that may encourage Invitrogen to continue to review opportunities to expand its operations in Australia.

Related News

Govt proposes cuts to R&D Tax Incentive

The Australian Government has reintroduced legislation that it claims will better target the...

AXT adds Alvéole's cell biology platform to its portfolio

The Alvéole platform allows users to convert an existing microscope into an automated...

Cell death pioneers win CSL Florey Medal

Andreas Strasser and David Vaux provided the first insights into the molecular mechanisms for...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd